Table 1. Trial characteristics of included abstracts.
| Characteristics | Pre- CONSORT-A (n = 285) |
Post- CONSORT-A (n = 214) |
||
|---|---|---|---|---|
| N | % | N | % | |
| Target diseasea | ||||
| Schizophrenia and psychotic disorders | 67 | 23·5 | 37 | 17·3 |
| Depressive disorders | 54 | 18·9 | 42 | 19·6 |
| Anxiety disorders | 31 | 10·9 | 18 | 8·4 |
| Bipolar and related disorders | 28 | 9·8 | 30 | 14·0 |
| Substance use and addictive disorders | 20 | 7·0 | 13 | 6·1 |
| Feeding and eating disorders | 12 | 4·2 | 6 | 2·8 |
| Trauma and stressor-related disorders | 11 | 3·9 | 11 | 5·1 |
| Obsessive-compulsive and related disorders | 8 | 2·8 | 5 | 2·3 |
| Others | 54 | 18·9 | 52 | 24·3 |
| Intervention*** | ||||
| Pharmacological | 185 | 64·9 | 112 | 52·3 |
| Psychological | 58 | 20·4 | 44 | 20·6 |
| Pharmacological and psychological | 23 | 8·1 | 14 | 6·5 |
| Others | 19 | 6·7 | 44 | 20·6 |
| Journal*** | ||||
| Arch Gen Psychiatryb | 25 | 8·8 | 6 | 2·8 |
| J Clin Psychiatry | 89 | 31·2 | 62 | 29·0 |
| Neuropsychopharmacology | 8 | 2·8 | 8 | 3·7 |
| Acta Psychiatr Scand | 6 | 2·1 | 3 | 1·4 |
| Psychol Med | 10 | 3·5 | 7 | 3·3 |
| Br J Psychiatry | 27 | 9·5 | 21 | 9·8 |
| Am J Psychiatry | 50 | 17·5 | 33 | 15·4 |
| Biol Psychiatry | 33 | 11·6 | 11 | 5·1 |
| BMJ | 6 | 2·1 | 1 | 0·5 |
| JAMA | 4 | 1·4 | 6 | 2·8 |
| Lancet | 0 | 0·0 | 5 | 2·3 |
| N Engl J Med | 2 | 0·7 | 2 | 0·9 |
| Others | 25 | 8·8 | 49 | 22·9 |
| Impact factor** | ||||
| Less than 5 | 10 | 3·5 | 16 | 7·5 |
| 5–10 | 155 | 54·4 | 134 | 62·6 |
| More than 10 | 120 | 42·1 | 64 | 29·9 |
| Number of Authors | ||||
| Less than 4 | 28 | 9·8 | 14 | 6·5 |
| 4–7 | 131 | 46·0 | 96 | 44·9 |
| More than 7 | 126 | 44·2 | 104 | 48·6 |
| Funding source*** | ||||
| Government/peer reviewed/cooperative groups | 143 | 50·2 | 163 | 76·2 |
| Industry | 88 | 30·9 | 29 | 13·6 |
| Both | 14 | 4·9 | 15 | 7·0 |
| No funding or none reported | 40 | 14·0 | 7 | 3·3 |
| Region of publication | ||||
| Europe | 76 | 26·7 | 73 | 34·1 |
| North America | 167 | 58·6 | 113 | 52·8 |
| Asia | 23 | 8·1 | 18 | 8·4 |
| Others | 19 | 6·7 | 10 | 4·7 |
| Centers | ||||
| Single center | 140 | 49·1 | 100 | 46·7 |
| Multicenter | 145 | 50·9 | 114 | 53·3 |
| Trial outcome | ||||
| Positive | 167 | 58·6 | 118 | 55·1 |
| Negative | 96 | 33·7 | 76 | 35·5 |
| Unclear | 22 | 7·7 | 20 | 9·3 |
| Abstract structure** | ||||
| Structured | 267 | 93·7 | 184 | 86·0 |
| Unstructured | 18 | 6·3 | 30 | 14·0 |
| Sample size | ||||
| Median (interquartile range) | 106 (50–254) | 106 (60–209·25) | ||
| CONSORT endorsement | ||||
| Yes | 251 | 88·1 | 180 | 84·1 |
| No | 34 | 11·9 | 34 | 15·9 |
| Word count limit | ||||
| <250 | 33 | 11·6 | 24 | 11·2 |
| ≥250 or no word limit | 252 | 88·4 | 190 | 88·8 |
a Classified in accordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
b Arch Gen Psychiatry was renamed JAMA psychiatry in 2013.
*P<0.05
**P<0.01
***P<0.001.
χ2 test or Fisher’s exact tests performed between pre-CONSORT-A (2005–2007) and post-CONSORT-A (2012–2014)